Association of matrix metalloproteinase‑9 and decorin expression with the infiltration of cervical cancer

  • Authors:
    • Tomohito Tanaka
    • Yoshito Terai
    • Masahide Ohmichi
  • View Affiliations

  • Published online on: November 15, 2018     https://doi.org/10.3892/ol.2018.9713
  • Pages: 1306-1312
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Matrix metalloproteinase‑9 (MMP9) has been recognized to be an important factor in cancer invasion and metastasis. In contrast, decorin has been revealed to inhibit primary tumor development. The aim of the present study was to investigate the function of MMP9 and decorin in cervical cancer. Three experiments were performed to analyze the function of MMP9 and decorin in the invasion of cervical cancer by: i) Analyzing the expression of MMP9 and decorin by immunohistochemistry in 100 cervical specimens; ii) determining the concentration of decorin by an enzyme‑linked immunosorbent assay (ELISA) using the human squamous cervical cancer cell line CaSki and human endometrial stromal cell line CRL4003 and iii) evaluating the invasion ability of CaSki cells in a cervical invasion model by an invasion assay. Immunohistochemistry revealed that MMP9 was overexpressed in microinvasive carcinoma (100.0%) but was less strongly expressed in normal or pre‑malignant squamous epithelium (0‑41.9%). In contrast, the activity of decorin in stroma adjacent to neoplastic cells was lower in microinvasive carcinoma (9.1%) compared with in normal or pre‑malignant lesions (74.2‑100.0%). An ELISA revealed that MMP9 released from CaSki cells resolved the decorin released from CRL4003 cells. An invasion assay demonstrated that the invasive ability of CaSki cells was suppressed by an MMP inhibitor, and decorin was released from CRL4003 cells. These data suggested that decorin prevented the invasion of malignant cells in uterine cervical cancer; however, MMP9 promotes cell invasion by destroying decorin.

Introduction

Matrix metalloproteinases (MMPs) are a family of zinc- and carcium-dependent proteolytic enzymes (1). These enzymes are normally involved in the breakdown of the extracellular matrix within the context of physiological tissue remodeling and angiogenesis (2). MMP9 is normally associated with bone remodeling (2) and dysregulated states, such as rheumatoid arthritis and osteosarcoma (3). It also has a strong influence on many phases of cancer progression, including angiogenesis, invasiveness and metastasis. An excessive production of MMP9 has been recognized to be an important factor in cancer invasion and metastasis (4).

Decorin is a member of the extracellular matrix small leucine-rich proteoglycan (SLRP) family of proteins that exists and functions mainly in the stroma and epithelial cells (5). It also has been found to play an important role in tumor development and progression, angiogenesis and metastasis (6). Several studies have shown that decorin inhibits primary tumor development and progression by antagonistically targeting multiple tyrosine kinase receptors, such as epidermal growth factor receptor (EGFR) (7).

The data in the pertinent literature show that members of the MMP family are able to cleave some SLRPs (811) including decorin (9). We hypothesize that cervical cancer cells display enhanced MMP9 expression, which results in infiltration to the extracellular matrix and uterine stroma destroying the basement membranes. The resolution of decorin by MMP9 from cancer cells promotes further infiltration, which results in further destruction of the extracellular matrix and stroma, where decorin is produced. The aim of the present study was to investigate the role of MMP9 and decorin in cervical cancer.

Materials and methods

Participants

The present study included 100 randomly selected patients who underwent cervical conization for squamous cell neoplasia at Osaka Medical College between 2010 and 2012. The Institutional Review Board approved this study (Ethics Committee of Osaka Medical College, 0277), and informed consent was obtained from all patients for the use of their tissue samples.

Expression of MMP9 and decorin by immunohistochemistry

The specimens were fixed in 10% formalin and embedded in paraffin. Serial sections cut out from paraffin-embedded blocks were used for routine histopathology. A 4-µm section was cut from a paraffin embedded block and immunohistochemically analyzed for the expression of MMP9 and decorin. Deparaffinized and rehydrated sections (4 µm) were autoclaved in 0.01 mol/l citrate buffer Ph 6.0 for 15 min at 121°C for antigen retrieval. Endogenous peroxidase activity was blocked with 0.3% solution hydrogen peroxide in methanol for 30 min. Tumor sections were incubated at 4°C for 12 h with anti-MMP9 rabbit polyclonal antibodies (AB13458; 1:50 dilutio; EMD Millipore, Billerica, MA, USA) and anti-decorin rabbit polyclonal antibodies (ab151988, 1:100 dilution; Abcam, Cambridge, MA, USA). The sections were washed with 1X phosphate-buffered saline (PBS) and incubated with Histofine simple stain MAX PO (multi; Nichirei, Tokyo, Japan) for 30 min at room temperature. Finally, the sections were washed with 1X PBS, signals and then visualized by incubation with H2O2/diaminobenzidine substrate solution for 5 min. The sections were counterstained with hematoxylin prior to dehydration and mounting.

The evaluation of the immunohistochemical data was performed by two independent observers who were blinded to the clinicopathological data. The expression of MMP9 for each sample was defined as detectable immunoreactions in cancer cells, as described previously (12). The evaluation of MMP9 expression was performed for stroma under the basement membrane or epithelial cells with no invasive neoplasia. In cases of invasive carcinoma, malignant cells or the stroma adjacent to malignant cells were evaluated. Briefly, the MMP9 expression was considered to be negative (no more than 10% of cells positive), low (more than 10% and up to 50% of cells positive) or high (more than 50% of cells positive). Based on these data, two groups were established: Negative MMP9 (no/low expression) and positive MMP9 expression (high expression).

The evaluation of the stromal decorin expression was also performed under the basement membrane with no invasive neoplasia. In cases of invasive carcinoma, the stroma adjacent to the malignant cells was evaluated. The expression of decorin was assessed using a semiquantitative system. Briefly, the decorin expression was scored as 0 (no stain), 1+ (weak immunoreactivity in more than 10% of stromal cells), 2+ (moderate immunoreactivity in more than 10% of stromal cells), or 3+ (strong immunoreactivity in more than 10% of stromal cells). Based on these data, two groups were established: Including a low decorin expression group (0 and 1+) and a high decorin expression group (2+ and 3+).

Cell lines

We used the human cervical cancer CaSki and the CRL-4003 immortalized human endometrial stromal cells, both purchased from the American Type Cultured Collection (Manassas, VA, USA). We also performed an STR polymorphism profiling analysis (Wakennyaku Co., Ibaraki, Japan) to confirm the cell line identity. These cells were cultured in growth media [DMEM/F12 10% FBS, 1% BD Insulin, Transferrin, Selenous (ITS) +Premix Universal Culture Supplement (catalog no: 354352; BD Biosciences, Franklin Lakes, NJ, USA)], in a humidified atmosphere of 5% CO2 with 95% air at 37°C.

Measurement of the concentration of decorin with an enzyme-linked immunosorbent (ELISA)

We used the cervical cancer cell line CaSki and endometrial stromal cell line CRL4003. DMEM was used as cell culture medium. A total of 106 CaSki cells and CRL4003 cells each were cultured at 37°C in a humidified, 5% CO2 atmosphere in DMEM for 96 h. CaSki culture medium was then obtained as medium containing MMP9. CRL4003 culture medium was also obtained as medium containing decorin. The concentration of decorin in the CRL4003 culture medium with or without CaSki culture medium or MMP inhibitor (MMP-9 inhibitor, ab142180; Abcam) was investigated by an ELISA. The experiment was carried out five times, and the concentration of decorin was expressed as the mean ± standard deviation (SD).

Influence of MMP9 and decorin on the invasion ability using an invasion assay

The invasive potential was assessed using an invasion assay. We examined the effects of MMP9 and decorin on the invasive potential of CaSki cells with or without CRL4003 cells and MMP inhibitor using this assay. A total of 5×105 CaSki cells were cultured at 37°C in a humidified, 5% CO2 atmosphere in serum-free DMEM for 24 h. These cells with or without MMP inhibitor were then seeded into upper wells coated with a thin layer of Matrigel. The lower chamber contained 600 µl of DMEM with or without 5×105 CRL4003 cells; we established four groups: CaSki, CaSki with CRL4003, CaSki with MMP inhibitor, CaSki with CRL4003 and MMP inhibitor. Following 24-h incubation at 37°C, noninvading cells on the surface of the Matrigel-coated membrane were removed by scraping with a cotton swab. Cells that migrated through the Matrigel were stained with hematoxylin. Following several washes with PBS, the stained cells were manually counted for two independent experiments. Each point represents the mean ± SD of four replicates.

Statistical analyses

All statistical analyses were performed using the JMP software package (v11.1.1; SAS Institute Inc, Tokyo, Japan). Continuous variables are expressed as the mean ± SD. The Mann-Whitney U-test was used to compare continuous variables between the two groups. When making multiple comparisons in datasets with continuous variables containing more than two groups, the Tukey honestly significant difference (HSD) was used. Fisher's exact test with Bonferroni's correction was used to compare frequencies between the three groups. Pearson's correlation coefficient was calculated to determine the correlation between two variables. P<0.05 was considered to indicate a statistically significant difference.

Results

Expression of MMP9 and decorin in surgical specimens

The immunochemical staining of MMP9 and decorin is shown in Fig. 1. In patients with cervical intraepithelial neoplasia (CIN) 1 (Fig. 1A), the expression of MMP9 was not seen under the basement membrane (Fig. 1B); however, decorin was expressed abundantly in the stroma (Fig. 1C). In contrast, in patients with microinvasive carcinoma (Fig. 1D), the expression of MMP9 was abundant (Fig. 1E); however, decorin was not seen in the stroma adjacent to malignant cells (Fig. 1F). The results of the immunohistochemical analyses are shown in Table I. The patients were categorized into three groups: those with normal to CIN2 were categorized as having low-grade neoplasia, those with CIN3 were categorized as being premalignant, and those with microinvasive carcinoma (FIGO stage IA1 squamous cervical cancer) were categorized as being malignant. Five patients had no neoplasia, 14 had CIN 1 and 14 had CIN 2; a total of 33 patients had normal to CIN2 (low-grade neoplasia group), 31 had CIN3 (premalignant group), and 36 had microinvasive carcinoma (malignant group). The mean ± SD age in the low-grade neoplasia, premalignant and malignant groups was 37.2±10.0, 40.9±11.2 and 38.6±10.4 years old, respectively. No significant difference was found between the groups. The rate of MMP9 positivity was 0% in the low-grade neoplasia group, 41.9% in the premalignant group and 100% in the malignant group. There were significant differences between each group (P<0.01). In contrast, the rate of high decorin expression was 100% in the low-grade neoplasia group, 74.2% in the premalignant group and 9.1% in the malignant group. There were significant differences between each group (P<0.01).

Table I.

Expression of MMP9 and decorin in uterine cervical neoplasm.

Table I.

Expression of MMP9 and decorin in uterine cervical neoplasm.

VariablesLow-grade neoplasia (n=33)Premalignant (n=31)Malignant (n=36)P-value
Agea, years37.2±10.040.9±11.238.6±10.4N.S.
Positive for MMP9 (%)0/33 (0)13/31 (41.9)36/36 (100)P<0.01
High decorin expression (%)33/33 (100)23/31 (74.2)3/36 (9.1)P<0.01

{ label (or @symbol) needed for fn[@id='tfn1-ol-0-0-9713'] } MMP9, Matrix metalloproteinase-9; N.S., not significant.

a Based on an analysis of variance (mean ± standard deviation).

Relationship between MMP9 and decorin

The concentration of decorin in CRL4003 culture medium with varying amounts of CaSki culture medium by an ELISA (Fig. 2A). When the ratio of CaSki culture medium to CRL4003 culture medium was 100, 50, 25, 10, 5, 3 and 1%, the concentration of decorin was 26.4±1.2, 138±6.4, 189±28, 368±61, 529±18, 582±81, 690±21 and 705±19 pg/ml, respectively. However, the concentration of decorin in CRL4003 culture medium with the same volume of CaSki culture medium and MMP inhibitor was 705±19 pg/ml. This value was not significantly different in comparison to the concentration of decorin in the CRL4003 cultured medium with 1% CaSki cultured medium (P=0.82). Pearson's correlation coefficient showed a strong correlation between the concentration of decorin and the amount of CaSki cultured medium (r=−0.84, P<0.05) (Fig. 2B). These findings indicate that the decorin released from CRL4003 cells was resolved by MMP9 released from CaSki cells.

Migration and invasion in the cervical invasion model

The results of migration and invasion assays is show in Fig. 3. The cell counts of CaSki, CaSki with CRL4003, CaSki with MMP inhibitor and CaSki with CRL4003 and MMP inhibitor were 32±12, 10±2.3, 7.8±1.6 and 4.4±1.1, respectively. CRL4003 culture medium and MMP inhibitor decreased the CaSki cell migration and invasion (P<0.01). CRL4003 culture medium with MMP inhibitor suppressed the CaSki cell migration and invasion the most effectively (P<0.01).

Discussion

In the present study, immunohistochemical analyses in patients with cervical cancer showed an increased MMP9 expression and a decreased decorin expression in the stroma adjacent to malignant cells. In vitro, the endometrial stromal cell line CRL4003 produced decorin, which suppressed cell invasion. Furthermore, the cervical cancer cell line CaSki produced MMP9, which promoted cell invasion and decomposed decorin.

MMPs are a family of metalloendopeptidases that break down the protein components of the extracellular matrix; they play an important role in tissue remodeling and degradation (1). Angiogenesis is one of the most important process of tumor growth and requires the degeneration and remodeling of the extracellular matrix, cell migration and proliferation, and tube formation (13); the role of MMP in tumor growth and progression is associated with angiogenesis. MMP9, which is over-expressed in cancer cells, is a potent gelatinase that has been shown to be associated with the process of tumor cell invasion and metastasis (14,15). The overexpression of MMP9 has been observed in pre-cancer and cancer lesion of the uterine cervix. The published literature states that MMP9 is overexpressed in more than 90% of squamous cell carcinomas and 83–100% of high-grade squamous intraepithelial lesions (HSILs) but is less strongly expressed in low-grade squamous intraepithelial lesions (LSILs) and normal squamous epithelium (13%) (1628). Most reports have shown that the activity of MMP9 tends to increase from normal cervix to HSIL and SCC, being more strongly expressed in more advanced stages (27,28). MMP9 is expressed in stromal cells and inflammatory cells around tumors (29). These findings suggest the importance of MMP9 in the pathogenesis of uterine cervical cancer; MMP9 affects various inflammatory cells infiltrating the tumor area, the extracellular matrix and stromal cells and proteins released from those cells.

Decorin, which is a member of the extracellular matrix SLPR, has been thought to act exclusively as a structural component (5). It is expressed in a wide range of connective tissues, including skin, bone, cartilaginous tissue and stroma and is secreted into the extracellular matrix (30,31). Fibrillar collagen, which is the main structural constituent of tendons, ligaments, skin and other connective tissues, is bound and cross-linked by decorin (3236). Decorin knockout mice show skin fragility and abnormal collagen fibril morphology (37), and a lack of decorin in these mice causes a significant delay in the healing of the excisional and incisional dermal wound compared to decorin wild-type mice (38). Furthermore, crossing decorin-null mice with P53-null mice caused early lethality of double-mutant animals because of massive organ infiltration by T-cell lymphoma (39). These findings indicate that decorin thus plays a role in tissue development.

As mentioned below, decorin has biological functions as a degenerator of endocytosis and inhibitor of tumor cell growth, migration, angiogenesis, endothelial cell proliferation and motility. Decorin affects signal transduction via erbB family receptors characterized by the stimulation of mitogen-activated protein kinases, mobilization of intracellular calcium and up-regulation of P21WAF1/CIP, a potent inhibitor of cyclin-dependent kinases, ultimately leading to growth suppression (31,4043). These signal transductions are associated with modulating cell proliferation, cell cycle progression and apoptosis. Decorin is known to be a promoter of matrix organization (44), which constitutes a physical barrier against the migration/motility of cancerous cells; decorin-collagen interactions prevent metastasis (45). Decorin is also known to be a negative regulator of signal transduction by interfering with growth factor binding including TGF-β (46,47); the synthesis of matrix molecules and the growth factor-dependent modulation of cell proliferation and migration is inhibited by decorin. For these reasons, decorin has recently emerged as a potential natural anticancer agent produced by normal host cells against cancer cells. There have been a number of reports about the anti-tumor effects of decorin on various malignant tumors, including uterine cervical carcinoma cells (48), ovarian cancer cells (49), breast cancer cells (50), colon carcinoma cells (51) and pancreatic cancer cells (52).

The published literature shows that MMPs digest decorin into fragments by cleaving within the leucine-rich region at multiple site (9). Those previous authors examined the susceptibility of decorin to five different MMPs. MMP2, MMP3 and MMP7 exhibited digestive activity for decorin, with MMP1 and MMP9 showing lower activity. In the present study, concentration of decorin in CRL4003 cultured medium was increased by MMP9 inhibitor. These data suggest that MMP9 not only directly digests decorin but also suppresses the production of decorin by impairing the tissue.

In conclusion, MMP9 was found to be overexpressed in uterine cervical cancer, but it was less strongly expressed in normal or pre-malignant squamous epithelium. In contrast, the activity of decorin in stroma adjacent to neoplastic cells was lower in microinvasive carcinoma than in normal or pre-malignant lesions. Decorin prevents the invasion of malignant cells, but MMP9 promotes cell invasion by destroying decorin, the extracellular matrix and stroma.

Acknowledgements

The authors would like to thank Dr. Yoshihiro Joshua Ono (Department of Obstetrics and Gynecology, Osaka Medical College, Osaka, Japan) for advice on the experimental design, and Ms. Junko Hayashi and Ms. Kumiko Satoh (Department of Obstetrics and Gynecology, Osaka Medical College) for their secretarial assistance.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed in the current study are available from the corresponding author on reasonable request.

Authors' contribution

TT and MO designed the study and performed the experimental data collection and analysis. TT and YT provided the diagnosis based on immunohistochemical analyses, and TT and MO wrote the paper.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of Osaka Medical College, and written informed consent to participate in the study was obtained from all patients involved.

Patient consent for publication

No identifying patient information is included in the published manuscript.

Competing interests

The authors declare that they have no competing interests.

Glossary

Abbreviations

Abbreviations:

MMP9

matrix metalloproteinase-9

ELISA

enzyme-linked immunosorbent assay

MMPs

matrix metalloproteinases

SLRP

small leucine-rich proteoglycan

EGFR

epidermal growth factor receptor

References

1 

Stamenkovic I: Extracellular matrix remodelling: The role of matrix metalloproteinases. J Pathol. 200:448–464. 2003. View Article : Google Scholar : PubMed/NCBI

2 

Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI

3 

Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA and Opdenakker G: Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol. 37:375–536. 2002. View Article : Google Scholar : PubMed/NCBI

4 

Moss Shuman LA, Jensen-Taubman S and Stetler-Stevenson WG: Matrix metalloproteinases: Changing roles in tumor progression and metastasis. Am J Pathol. 181:1895–1899. 2012. View Article : Google Scholar : PubMed/NCBI

5 

Schaefer L and Iozzo RV: Biological functions of the small leucine-rich proteoglycans: From genetics to signal transduction. J Biol Chem. 283:21305–21309. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Bi XL and Yang W: Biological functions of decorin in cancer. Chin J Cancer. 32:266–269. 2013. View Article : Google Scholar : PubMed/NCBI

7 

Goldoni S, Humphries A, Nyström A, Sattar S, Owens RT, McQuillan DJ, Ireton K and Iozzo RV: Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol. 185:743–754. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Monfort J, Tardif G, Reboul P, Mineau F, Roughley P, Pelletier JP and Martel-Pelletier J: Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease-13: Identification of a new biglycan cleavage site. Arthritis Res Ther. 8:R262006. View Article : Google Scholar : PubMed/NCBI

9 

Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD and Okada Y: Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J. 322:809–814. 1997. View Article : Google Scholar : PubMed/NCBI

10 

Heathfield TF, Onnerfjord P, Dahlberg L and Heinegård D: Cleavage of fibromodulin in cartilage explants involves removal of the N-terminal tyrosine sulfate-rich region by proteolysis at a site that is sensitive to matrix metalloproteinase-13. J Biol Chem. 279:6286–6295. 2004. View Article : Google Scholar : PubMed/NCBI

11 

Li Y, Aoki T, Mori Y, Ahmad M, Miyamori H, Takino T and Sato H: Cleavage of lumican by membrane-type matrix metalloproteinase-1 abrogates this proteoglycan-mediated suppression of tumor cell colony formation in soft agar. Cancer Res. 64:7058–7064. 2004. View Article : Google Scholar : PubMed/NCBI

12 

Shirabe K, Shimada M, Kajiyama K, Hasegawa H, Gion T, Ikeda Y, Takenaka K and Sugimachi K: Expression of matrix metalloproteinase-9 in surgically resected intrahepatic cholangiocarcinoma. Surgery. 126:842–846. 1999. View Article : Google Scholar : PubMed/NCBI

13 

Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med. 6:389–395. 2000. View Article : Google Scholar : PubMed/NCBI

14 

Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 284:67–68. 1980. View Article : Google Scholar : PubMed/NCBI

15 

Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG and Quaranta V: Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 277:225–228. 1997. View Article : Google Scholar : PubMed/NCBI

16 

Sheu BC, Lien HC, Ho HN, Lin HH, Chow SN, Huang SC and Hsu SM: Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res. 63:6537–6542. 2003.PubMed/NCBI

17 

Wang PH, Ko JL, Tsai HT, Yang SF, Han CP, Lin LY and Chen GD: Clinical significance of matrix metalloproteinase-2 in cancer of uterine cervix: A semiquantitative study of immunoreactivities using tissue array. Gynecol Oncol. 108:533–542. 2008. View Article : Google Scholar : PubMed/NCBI

18 

Gaiotto MA, Focchi J, Ribalta JL, Stavale JN, Baracat EC, Lima GR and da Silva Guerreiro ID: Comparative study of MMP-2 (matrix metalloproteinase 2) immune expression in normal uterine cervix, intraepithelial neoplasias and squamous cells cervical carcinoma. Am J Obstet Gynecol. 190:1278–1282. 2004. View Article : Google Scholar : PubMed/NCBI

19 

Argüello-Ramírez J, Pérez-Cárdenas E, Delgado-Chávez R, Solorza-Luna G, Villa-Treviño S and Arenas-Huertero F: Matrix metalloproteinases-2, −a3 and −9 secreted by explants of benign and malignant lesions of the uterine cervix. Int J Gynecol Cancer. 14:333–340. 2004. View Article : Google Scholar : PubMed/NCBI

20 

Sato T, Sakai T, Noguchi Y, Takita M, Hirakawa S and Ito A: Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol. 92:47–56. 2004. View Article : Google Scholar : PubMed/NCBI

21 

Ahmed N, Riley C, Oliva K, Barker G, Quinn MA and Rice GE: Expression and localization of alphavbeta6 integrin in extraplacental fetal membranes: Possible role in human parturition. Mol Hum Reprod. 10:173–179. 2004. View Article : Google Scholar : PubMed/NCBI

22 

Yang SF, Wang PH, Lin LY, Ko JL, Chen GD, Yang JS, Lee HS and Hsieh YS: A significant elevation of plasma level of matrix metalloproteinase-9 in patients with high-grade intraepithelial neoplasia and early squamous cell carcinoma of the uterine cervix. Reprod Sci. 14:710–718. 2007. View Article : Google Scholar : PubMed/NCBI

23 

Baltazar-Rodriguez LM, Anaya-Ventura A, Andrade-Soto M, Monrroy-Guizar EA, Bautista-Lam JR, Jonguitud-Olguin G, Cepeda-Lopez FR, Centeno-Aguilar VA, Gonzalez-Hernandez NA, Soriano-Hernández AD, et al: Polymorphism in the matrix metalloproteinase-2 gene promoter is associated with cervical neoplasm risk in Mexican women. Biochem Genet. 46:137–144. 2008. View Article : Google Scholar : PubMed/NCBI

24 

Rauvala M, Aglund K, Puistola U, Turpeenniemi-Hujanen T, Horvath G, Willén R and Stendahl U: Matrix metalloproteinases-2 and −9 in cervical cancer: Different roles in tumor progression. Int J Gynecol Cancer. 16:1297–1302. 2006. View Article : Google Scholar : PubMed/NCBI

25 

Nasr M, Ayyad SB, El-Lamie IK and Mikhail MY: Expression of matrix metalloproteinase-2 in preinvasive and invasive carcinoma of the uterine cervix. Eur J Gynaecol Oncol. 26:199–202. 2005.PubMed/NCBI

26 

Yoshida H, Sumi T, Hyun Y, Nakagawa E, Hattori K, Yasui T, Morimura M, Honda K, Nakatani T and Ishiko O: Expression of survivin and matrix metalloproteinases in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Oncol Rep. 10:45–49. 2003.PubMed/NCBI

27 

Talvensaari-Mattila A, Turpeenniemi-Hujanen T and Puistola U: Matrix metalloproteinase 9 and relapse in patients with early stage squamous cervical carcinoma. Int J Gynaecol Obstet. 91:75–76. 2005. View Article : Google Scholar : PubMed/NCBI

28 

Talvensaari-Mattila A and Turpeenniemi-Hujanen T: Matrix metalloproteinase 9 in the uterine cervix during tumor progression. Int J Gynaecol Obstet. 92:83–84. 2006. View Article : Google Scholar : PubMed/NCBI

29 

Tellier E, Nègre-Salvayre A, Bocquet B, Itohara S, Hannun YA, Salvayre R and Augé N: Role for furin in tumor necrosis factor alpha-induced activation of the matrix metalloproteinase/sphingolipid mitogenic pathway. Mol Cell Biol. 27:2997–3007. 2007. View Article : Google Scholar : PubMed/NCBI

30 

Corsi A, Xu T, Chen XD, Boyde A, Liang J, Mankani M, Sommer B, Iozzo RV, Eichstetter I, Robey PG, et al: Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J Bone Miner Res. 17:1180–1189. 2002. View Article : Google Scholar : PubMed/NCBI

31 

Iozzo RV: The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J Biol Chem. 274:18843–18846. 1999. View Article : Google Scholar : PubMed/NCBI

32 

Keene DR, Antonio San JD, Mayne R, McQuillan DJ, Sarris G, Santoro SA and Iozzo RV: Decorin binds near the C terminus of type I collagen. J Biol Chem. 275:21801–21804. 2000. View Article : Google Scholar : PubMed/NCBI

33 

Bidanset DJ, Guidry C, Rosenberg LC, Choi HU, Timpl R and Hook M: Binding of the proteoglycan decorin to collagen type VI. J Biol Chem. 267:5250–5256. 1992.PubMed/NCBI

34 

Schonherr E, Hausser H, Beavan L and Kresse H: Decorin-type I collagen interaction. Presence of separate core protein-binding domains. J Biol Chem. 270:8877–8883. 1995. View Article : Google Scholar : PubMed/NCBI

35 

Kinsella MG, Bressler SL and Wight TN: The regulated synthesis of versican, decorin, and biglycan: Extracellular matrix proteoglycans that influence cellular phenotype. Crit Rev Eukaryot Gene Expr. 14:203–234. 2004. View Article : Google Scholar : PubMed/NCBI

36 

Nareyeck G, Seidler DG, Troyer D, Rauterberg J, Kresse H and Schönherr E: Differential interactions of decorin and decorin mutants with type I and type VI collagens. Eur J Biochem. 271:3389–3398. 2004. View Article : Google Scholar : PubMed/NCBI

37 

Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE and Iozzo RV: Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol. 136:729–743. 1997. View Article : Google Scholar : PubMed/NCBI

38 

Järveläinen H, Puolakkainen P, Pakkanen S, Brown EL, Höök M, Iozzo RV, Sage EH and Wight TN: A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen. 14:443–452. 2006. View Article : Google Scholar : PubMed/NCBI

39 

Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, Calabretta B and Eichstetter I: Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci USA. 96:3092–3097. 1999. View Article : Google Scholar : PubMed/NCBI

40 

Csordás G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, Nugent MA, Hajnoczky G and Iozzo RV: Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem. 275:32879–32887. 2000. View Article : Google Scholar : PubMed/NCBI

41 

Zhu JX, Goldoni S, Bix G, Owens RT, McQuillan DJ, Reed CC and Iozzo RV: Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J Biol Chem. 280:32468–32479. 2005. View Article : Google Scholar : PubMed/NCBI

42 

Seidler DG, Faiyaz-Ul-Haque M, Hansen U, Yip GW, Zaidi SH, Teebi AS, Kiesel L and Götte M: Defective glycosylation of decorin and biglycan, altered collagen structure, and abnormal phenotype of the skin fibroblasts of an Ehlers-Danlos syndrome patient carrying the novel Arg270Cys substitution in galactosyltransferase I (beta4GalT-7). J Mol Med (Berl). 84:583–594. 2006. View Article : Google Scholar : PubMed/NCBI

43 

Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, Owens RT, McQuillan DJ and Iozzo RV: Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem. 281:26408–26418. 2006. View Article : Google Scholar : PubMed/NCBI

44 

Koninger J, Giese T, di Mola FF, Wente MN, Esposito I, Bachem MG, Giese NA, Büchler MW and Friess H: Pancreatic tumor cells influence the composition of the extracellular matrix. Biochem Biophys Res Commun. 322:943–949. 2004. View Article : Google Scholar : PubMed/NCBI

45 

Skandalis SS, Kletsas D, Kyriakopoulou D, Stavropoulos M and Theocharis DA: The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications may be closely associated with the malignant phenotype of pancreatic cancer. Biochim Biophys Acta. 1760:1217–1225. 2006. View Article : Google Scholar : PubMed/NCBI

46 

Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi YU, Pierschbacher MD and Ruoslahti E: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature. 360:361–364. 1992. View Article : Google Scholar : PubMed/NCBI

47 

Hildebrand A, Romaris M, Rasmussen LM, Heinegård D, Twardzik DR, Border WA and Ruoslahti E: Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J. 302:527–534. 1994. View Article : Google Scholar : PubMed/NCBI

48 

Grant DS, Yenisey C, Rose RW, Tootell M, Santra M and Iozzo RV: Decorin suppresses tumor cell-mediated angiogenesis. Oncogene. 21:4765–4777. 2002. View Article : Google Scholar : PubMed/NCBI

49 

Nash MA, Loercher AE and Freedman RS: In vitro growth inhibition of ovarian cancer cells by decorin: Synergism of action between decorin and carboplatin. Cancer Res. 59:6192–6196. 1999.PubMed/NCBI

50 

Reed CC, Waterhouse A, Kirby S, Kay P, Owens RT, McQuillan DJ and Iozzo RV: Decorin prevents metastatic spreading of breast cancer. Oncogene. 24:1104–1110. 2005. View Article : Google Scholar : PubMed/NCBI

51 

Santra M, Skorski T, Calabretta B, Lattime EC and Iozzo RV: De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci USA. 92:7016–7020. 1995. View Article : Google Scholar : PubMed/NCBI

52 

Köninger J, Giese NA, di Mola FF, Berberat P, Giese T, Esposito I, Bachem MG, Buchler MW and Friess H: Overexpressed decorin in pancreatic cancer: Potential tumor growth inhibition and attenuation of chemotherapeutic action. Clin Cancer Res. 10:4776–4783. 2004. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

January-2019
Volume 17 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tanaka T, Terai Y and Ohmichi M: Association of matrix metalloproteinase‑9 and decorin expression with the infiltration of cervical cancer. Oncol Lett 17: 1306-1312, 2019.
APA
Tanaka, T., Terai, Y., & Ohmichi, M. (2019). Association of matrix metalloproteinase‑9 and decorin expression with the infiltration of cervical cancer. Oncology Letters, 17, 1306-1312. https://doi.org/10.3892/ol.2018.9713
MLA
Tanaka, T., Terai, Y., Ohmichi, M."Association of matrix metalloproteinase‑9 and decorin expression with the infiltration of cervical cancer". Oncology Letters 17.1 (2019): 1306-1312.
Chicago
Tanaka, T., Terai, Y., Ohmichi, M."Association of matrix metalloproteinase‑9 and decorin expression with the infiltration of cervical cancer". Oncology Letters 17, no. 1 (2019): 1306-1312. https://doi.org/10.3892/ol.2018.9713